Search for a command to run...
Concentrated bone marrow aspirate (cBMA), platelet‐rich plasma (PRP), and adipose‐derived mesenchymal stem cells (AD‐MSCs) are biologic products commonly used in orthopaedic and sports medicine due to their distinct cellular and molecular compositions. cBMA is obtained by aspirating and centrifuging bone marrow, concentrating a mixture of mesenchymal stem cells (MSCs), hematopoietic stem cells, platelets, and growth factors such as vascular endothelial growth factor (VEGF) and transforming growth factor‐beta (TGF‐β), which support angiogenesis, immunomodulation, and tissue regeneration. The MSCs within BMC can differentiate into osteoblasts, chondrocytes, and fibroblasts, with the potential to assist with tissue repair. PRP is derived from whole blood processed to reduce platelet concentrations while preserving plasma proteins like fibrinogen and albumin. It can be formulated as leukocyte‐rich (LR‐PRP) or leukocyte‐poor (LP‐PRP), offering different biologic effects: LR‐PRP may enhance early inflammation useful in tendon healing, while LP‐PRP minimizes inflammatory cytokines, making it favorable for intra‐articular applications. AD‐MSCs, isolated from lipoaspirated fat tissue, are a high‐yield, minimally invasive source of multipotent stromal cells capable of differentiating into multiple lineages. They secrete bioactive molecules including VEGF, hepatocyte growth factor (HGF), and interleukin‐10 (IL‐10), exerting strong paracrine and immunomodulatory effects. Compared to bone marrow MSCs, AD‐MSCs provide easier harvest, higher yields, and robust regenerative potential via both cellular and extracellular vesicle mechanisms. Collectively, these biologics represent a potential to deliver a “biologic pharmacy” of nutrients, biologic molecules, and growth factors to promote healing and reduce inflammation at a site of degeneration, injury, or surgical repair.